Amylin has announced a corporate restructuring that will result in a reduction of workforces by 25%, or 340 employees. “Sales revenues have not met the expectations we had when we scaled up our organization,” said Daniel Bradbury, president and CEO at Amylin, in a statement.
A Pfizer manufacturing plant in Indiana has been put up for sale. The plant most recently manufactured Exubera, an inhaled insulin therapy, which didn’t catch on with patients.
